Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC, is developing products to treat several diseases and their debilitating comorbidities associated with reduced quality of life, increased medical cost, and significant mortality. A portfolio of hematology and oncology products is currently in development.
Prolong has four products in development for hematology and oncology indications. Its lead product, SANGUINATE®, is in clinical development with a focus on treating sickle cell disease and other disorders caused by anemia or hypoxia/ischemia.
Please visit our Products page for more information on SANGUINATE® as well as the other products in our pipeline and current clinical status.
Originally established in 2005 as a research lab, Prolong has emerged as a mature, privately held biotech company. Led by a team of successful pharmaceutical executives, Prolong has multiple active clinical development programs progressing and has a large scale cGMP manufacturing facilities on-line.
Our leadership team has led and been associated with a number of successful pharmaceutical and biotechnology companies. Prolong’s senior management includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, which is now responsible for the development of many drugs improving the quality of life for sufferers of hepatitis, kidney disease, and a number of other life-threatening diseases.